Stock data
Iovance Biotherapeutics, Inc. (IOVA)
Iovance Biotherapeutics, Inc. (IOVA) reported revenue of US$263.50M and net income of -US$390.98M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$263.50M | — | -US$403.36M | -US$390.98M | — |
| 2024 | US$164.07M | — | -US$395.28M | -US$372.18M | — |
| 2023 | US$1.19M | — | -US$460.56M | -US$444.04M | — |
| 2022 | — | — | -US$398.88M | -US$395.89M | — |
| 2021 | — | — | -US$342.70M | -US$342.25M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$99.31M | -US$47.31M | — |
| 2026-03-31 | US$71.43M | -US$79.05M | — |
| 2025-12-31 | US$86.77M | -US$71.90M | — |
| 2025-09-30 | US$67.45M | -US$91.25M | — |
| 2025-06-30 | US$59.95M | -US$111.66M | — |
| 2025-03-31 | US$49.32M | -US$116.16M | — |
| 2024-12-31 | US$73.69M | -US$78.56M | — |
| 2024-09-30 | US$58.55M | -US$83.54M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.